https://www.avient.com/resources/safety-data-sheets?page=5870
Avient has transitioned our Material Safety Data Sheets (MSDSs) to Safety Data Sheets (SDSs) for our manufactured products to meet the requirements of the Globally Harmonized System of Classification and Labeling of Chemicals (GHS), and CLP classification in Europe.
Technical Data Sheets
Safety Data Sheets
https://www.avient.com/resources/safety-data-sheets?page=5654
Avient has transitioned our Material Safety Data Sheets (MSDSs) to Safety Data Sheets (SDSs) for our manufactured products to meet the requirements of the Globally Harmonized System of Classification and Labeling of Chemicals (GHS), and CLP classification in Europe.
Technical Data Sheets
Safety Data Sheets
https://www.avient.com/resources/safety-data-sheets?page=4331
Avient has transitioned our Material Safety Data Sheets (MSDSs) to Safety Data Sheets (SDSs) for our manufactured products to meet the requirements of the Globally Harmonized System of Classification and Labeling of Chemicals (GHS), and CLP classification in Europe.
Technical Data Sheets
Safety Data Sheets
https://www.avient.com/resources/safety-data-sheets?page=7116
Avient has transitioned our Material Safety Data Sheets (MSDSs) to Safety Data Sheets (SDSs) for our manufactured products to meet the requirements of the Globally Harmonized System of Classification and Labeling of Chemicals (GHS), and CLP classification in Europe.
Technical Data Sheets
Safety Data Sheets
https://www.avient.com/resources/safety-data-sheets?page=7198
Avient has transitioned our Material Safety Data Sheets (MSDSs) to Safety Data Sheets (SDSs) for our manufactured products to meet the requirements of the Globally Harmonized System of Classification and Labeling of Chemicals (GHS), and CLP classification in Europe.
Technical Data Sheets
Safety Data Sheets
https://www.avient.com/sites/default/files/2021-04/avnt-fourth-quarter-2020-news-release.pdf
We held our priorities firm by keeping health and safety first, providing world-class service to our customers, and utilizing our unique position to aid in recovery efforts as an essential supplier throughout the world.” 2021 Outlook Commenting on the Company’s 2021 outlook, Mr.
Rose Vice President, Corporate Communications Avient Corporation +1 440-930-3162 kyle.rose@avient.com 5 Attachment 1 Avient Corporation Summary of Condensed Consolidated Statements of Income (Unaudited) (In millions, except per share data) Three Months Ended December 31, Year Ended December 31, 2020 2019 2020 2019 Sales $ 997.0 $ 658.6 $ 3,242.1 $ 2,862.7 Operating Income 65.0 20.5 189.3 156.8 Net income from continuing operations attributable to Avient shareholders 74.2 6.4 132.0 75.5 Basic earnings per share from continuing operations attributable to Avient shareholders $ 0.81 $ 0.08 $ 1.47 $ 0.98 Diluted earnings per share from continuing operations attributable to Avient shareholders $ 0.81 $ 0.08 $ 1.46 $ 0.97 Senior management uses comparisons of adjusted net income from continuing operations attributable to Avient shareholders and diluted adjusted earnings per share (EPS) from continuing operations attributable to Avient shareholders, excluding special items, to assess performance and facilitate comparability of results.
Three Months Ended December 31, Year Ended December 31, 2020 2019 2020 2019 Sales: Color, Additives and Inks $ 525.8 $ 226.7 $ 1,502.9 $ 1,003.8 Specialty Engineered Materials 190.6 177.5 708.8 745.7 Distribution 305.1 272.4 1,110.3 1,192.2 Corporate and eliminations (24.5) (18.0) (79.9) (79.0) Sales $ 997.0 $ 658.6 $ 3,242.1 $ 2,862.7 Gross margin: Color, Additives and Inks $ 164.3 $ 73.9 $ 484.4 $ 338.4 Specialty Engineered Materials 59.1 47.7 207.6 200.2 Distribution 32.4 31.0 124.0 132.1 Corporate and eliminations (2.9) 0.7 (31.7) (13.5) Gross margin $ 252.9 $ 153.3 $ 784.3 $ 657.2 Selling and administrative expense: Color, Additives and Inks $ 106.8 $ 46.7 $ 303.6 $ 191.0 Specialty Engineered Materials 28.7 28.9 113.2 116.5 Distribution 14.4 14.0 54.5 56.7 Corporate and eliminations 38.0 43.2 123.7 136.2 Selling and administrative expense $ 187.9 $ 132.8 $ 595.0 $ 500.4 Operating income: Color, Additives and Inks $ 57.5 $ 27.2 $ 180.8 $ 147.4 Specialty Engineered Materials 30.4 18.8 94.4 83.7 Distribution 18.0 17.0 69.5 75.4 Corporate and eliminations (40.9) (42.5) (155.4) (149.7) Operating income $ 65.0 $ 20.5 $ 189.3 $ 156.8 11 Attachment 7 Avient Corporation Reconciliation of Non-GAAP Financial Measures (Unaudited) (In millions, except per share data) Senior management uses gross margin before special items and operating income before special items to assess performance and allocate resources because senior management believes that these measures are useful in understanding current profitability levels and how it may serve as a basis for future performance.
https://www.avient.com/sites/default/files/2024-06/OnColor UL 94 Colorants Brochure.pdf
ONCOLOR™ UL 94 COLORANTS DESIGN & SAFETY High-impact colors and cutting-edge design are hugely important to the success of today’s sleek, modern electrical and electronic products.
At the same time, manufacturers also need to consider product safety and regulatory compliance.
The comprehensive concentrate portfolio provided by Avient meets customer requirements and improves the safety for consumers of electrical and electronic devices. * Solutions also sold as Renol™ UL 94 Colorants IMPORTANCE OF UL 94 There are two major established norms in the E&E industry that relate to plastics flammability: the IEC 60695 standard and the UL 94 standard.
https://www.avient.com/sites/default/files/2020-10/2020-gravi-tech-design-guide-.pdf
Process Optimization . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20 Machine Sizing. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20 Four Main Plastic Variables. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20 Establishing a Process – The Scientific Molding Method. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21 Process Distinctions. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23 TABLE OF CONTENTS Design Guide 3 Chapter 6.
VALUE SOLUTION Improve safety and reduce costs with Gravi-Tech formulations When Gravi-Tech polymer metal composites are substituted for lead, manufacturers can avoid the regulatory, disposal and employee exposure challenges associated with lead.
If the material is shear-sensitive, consult the material data sheet or processing guide for instructions to set recovery time • The cooling time should only be 1–2 seconds longer than the screw recovery time, unless dictated by dimensional stability or part thickness Minimize Clamp Pressure This step is done to reduce the amount of energy used by the machine. • Reduce the clamp tonnage until flash is seen around the parting line, then increase the clamp tonnage by 5-10% Minimize Cycle Time • Mold Open/Close – Should be as fast as possible, without slamming, and still produce a nice fluid motion • Ejector Speed – As fast as possible, without influencing part quality • Ejector Stroke – Only stroke the ejectors as many times as needed to separate the part from the core - i.e.
https://www.avient.com/sites/default/files/2022-06/Colorant Chromatics FEP UV Laser Marking Product Bulletin.pdf
For identification purposes or safety reasons, these cables often need to be marked.
Examples include: • Data transmission cables • Optical fiber cables PRODUCT BULLETIN 1.844.4AVIENT www.avient.com Copyright © 2022, Avient Corporation.
https://www.avient.com/sites/default/files/2022-08/Humotech Robotic Prosthetic Case Study.pdf
In the case of prosthetic legs and feet, the device must align with the patient’s natural gait, activity level, and mobility goals, while also maintaining comfort and safety.
This process has traditionally been conducted through trial and error with clinicians, using commercially available prostheses with access only to biased data and knowledge from past patient feedback.